GBT Global Blood Therapeutics Inc

Price (delayed)

$37.79

Market cap

$2.35B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.04

Enterprise value

$2.14B

Sector: Healthcare
Industry: Biotechnology

Highlights

Global Blood Therapeutics's gross profit has increased by 20% from the previous quarter
GBT's revenue is up by 20% since the previous quarter
The debt is up by 49% year-on-year
GBT's equity is down by 31% YoY and by 13% QoQ

Key stats

What are the main financial stats of GBT
Market
Shares outstanding
62.27M
Market cap
$2.35B
Enterprise value
$2.14B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.47
Price to sales (P/S)
15.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.37
Earnings
Revenue
$148.73M
EBIT
-$238.27M
EBITDA
-$228.34M
Free cash flow
-$219.86M
Per share
EPS
-$4.04
Free cash flow per share
-$3.54
Book value per share
$5.84
Revenue per share
$2.39
TBVPS
$10.47
Balance sheet
Total assets
$649.9M
Total liabilities
$286.7M
Debt
$231.95M
Equity
$363.2M
Working capital
$499.17M
Liquidity
Debt to equity
0.64
Current ratio
9.47
Quick ratio
8.53
Net debt/EBITDA
0.94
Margins
EBITDA margin
-153.5%
Gross margin
98.4%
Net margin
-167.7%
Operating margin
-162.8%
Efficiency
Return on assets
-35.8%
Return on equity
-57.6%
Return on invested capital
-62.6%
Return on capital employed
-40.3%
Return on sales
-160.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GBT stock price

How has the Global Blood Therapeutics stock price performed over time
Intraday
0.85%
1 week
-3.05%
1 month
-7.31%
1 year
-50.95%
YTD
-12.75%
QTD
-7.26%

Financial performance

How have Global Blood Therapeutics's revenue and profit performed over time
Revenue
$148.73M
Gross profit
$146.29M
Operating income
-$242.07M
Net income
-$249.46M
Gross margin
98.4%
Net margin
-167.7%
Global Blood Therapeutics's operating margin has surged by 91% YoY and by 17% QoQ
The net margin has soared by 91% year-on-year and by 16% since the previous quarter
Global Blood Therapeutics's operating income has increased by 22% YoY
Global Blood Therapeutics's gross profit has increased by 20% from the previous quarter

Growth

What is Global Blood Therapeutics's growth rate over time

Valuation

What is Global Blood Therapeutics stock price valuation
P/E
N/A
P/B
6.47
P/S
15.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.37
The EPS has grown by 17% YoY
GBT's equity is down by 31% YoY and by 13% QoQ
The P/B is 27% above the 5-year quarterly average of 5.1 but 9% below the last 4 quarters average of 7.1
GBT's price to sales (P/S) is 60% lower than its last 4 quarters average of 39.9
GBT's revenue is up by 20% since the previous quarter

Efficiency

How efficient is Global Blood Therapeutics business performance
The ROS has soared by 91% YoY and by 17% from the previous quarter
The company's return on equity fell by 22% YoY and by 10% QoQ
The company's return on invested capital fell by 10% QoQ and by 5% YoY
The ROA has grown by 7% YoY but it has contracted by 4.1% from the previous quarter

Dividends

What is GBT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GBT.

Financial health

How did Global Blood Therapeutics financials performed over time
Global Blood Therapeutics's total assets is 127% higher than its total liabilities
Global Blood Therapeutics's total liabilities has increased by 32% YoY but it has decreased by 7% QoQ
The company's current ratio rose by 18% QoQ and by 4.4% YoY
The debt is 36% smaller than the equity
The debt to equity has soared by 113% YoY and by 14% from the previous quarter
The debt is up by 49% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.